Olema is currently developing a "cancer" drug that suppresses the body's production of Estrogen. Now this could be useful for breast cancer treatment but the real target audience, in my opinion, is hormone replacement therapy for gender transition. I don't necessarily endorse this kind of product but given the corporate and governmental policies surrounding the...
Price tested prior resistance and bounced with a tremendous volume spike.
OBV has bullish divergence since the downtrend began in late Feb.
Looking for support to hold (2.99) and price to break 3.49 to enter a swing trade.
target: 3.80, 4.06, 4.67
